Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
05/08/2026 13:17
BRIEF-Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe Aug 5 (Reuters) -
NEWAMSTERDAM PHARMA COMPANY N.V. - ANNOUNCES POSITIVE CHMP OPINION FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE
NEWAMSTERDAM PHARMA COMPANY N.V. - PREVAIL INTERIM ANALYSIS PLANNED FOR Q4 2026, RESULT EXPECTED Q1 2027
NEWAMSTERDAM PHARMA COMPANY N.V. - TOPLINE DATA FROM RUBENS PHASE 3 EXPECTED BY YEAR-END 2026
Source text: ID:nGNX8k3DDr
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NewAmsterdam Pharma
See all newsBrief: Menarini Group & Newamsterdam Pharma Receive European Commission Approval For Ubeslo And Evlarco
Amgen falls after Novartis trial setback, BMO downgrade
Brief: Newamsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
Brief: NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)